Review of pharmacological inhibition of thyroid cancer metabolism
作者机构：Department of PharmacologyLarner College of MedicineBurlingtonVT 05405USA University of Vermont Cancer CenterBurlingtonVT 05405USA
出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)
年 卷 期：2021年第7卷第1期
页 面：640-658页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported in part by the University of Vermont Cancer Center
主 题：Thyroid cancer tumor metabolism metabolic inhibitors Warburg effect cell signaling
摘 要：Thyroid cancer(TC)is the most common malignancy of the endocrine system and has been rapidly increasing in incidence over the past few *** TCs metastasize quickly and often levy poor prognoses,as they are frequently resistant to first-line treatment *** diagnosed with aggressive,dedifferentiated TC have a prognosis of under a year with the most current treatment *** many cancers,TCs also exhibit altered cell metabolism,which enhances the cell’s ability to generate energy,protect against reactive oxygen species,and synthesize macromolecules such as lipids,proteins,and nucleotides for *** and enzyme profiling of TC tissues and cell lines have uncovered several dysregulated metabolic pathways such as glycolysis,the pentose phosphate pathway,glutamine metabolism,and pyrimidine *** aberrations are most often due to overexpression of rate-limiting enzymes or metabolite *** pathways pose attractive therapeutic targets in aggressive TC and may serve to work in tandem with standard therapeutics such as kinase inhibitors depending on the genetic,metabolic,and signaling backgrounds of individual *** studies are needed to clearly delineate altered metabolic targets across TC subtypes for implementing therapeutic metabolic inhibitors that have shown success in other aggressive tumors.
维普期刊数据库